Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular imaging using PET for breast cancer.
Kurihara H, Shimizu C, Miyakita Y, Yoshida M, Hamada A, Kanayama Y, Yonemori K, Hashimoto J, Tani H, Kodaira M, Yunokawa M, Yamamoto H, Watanabe Y, Fujiwara Y, Tamura K. Kurihara H, et al. Among authors: kodaira m. Breast Cancer. 2016 Jan;23(1):24-32. doi: 10.1007/s12282-015-0613-z. Epub 2015 Apr 28. Breast Cancer. 2016. PMID: 25917108 Review.
64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.
Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, Honda N, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Hasegawa K, Kanayama Y, Nozaki S, Kinoshita T, Wada Y, Tazawa S, Takahashi K, Watanabe Y, Fujiwara Y. Tamura K, et al. Among authors: kodaira m. J Nucl Med. 2013 Nov;54(11):1869-75. doi: 10.2967/jnumed.112.118612. Epub 2013 Sep 12. J Nucl Med. 2013. PMID: 24029656 Free article.
(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients.
Kurihara H, Hamada A, Yoshida M, Shimma S, Hashimoto J, Yonemori K, Tani H, Miyakita Y, Kanayama Y, Wada Y, Kodaira M, Yunokawa M, Yamamoto H, Shimizu C, Takahashi K, Watanabe Y, Fujiwara Y, Tamura K. Kurihara H, et al. Among authors: kodaira m. EJNMMI Res. 2015 Mar 12;5:8. doi: 10.1186/s13550-015-0082-6. eCollection 2015. EJNMMI Res. 2015. PMID: 25853014 Free PMC article.
Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.
Tamura K, Kodaira M, Shimizu C, Yonemori K, Yunokawa M, Shimomura A, Kobayashi T, Nakano K, Tomomatsu J, Ito Y, Tanaka J, Kuriki H, Gu Z, Takahashi S. Tamura K, et al. Among authors: kodaira m. Cancer Sci. 2018 May;109(5):1592-1601. doi: 10.1111/cas.13561. Epub 2018 Mar 31. Cancer Sci. 2018. PMID: 29500843 Free PMC article. Clinical Trial.
Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
Inagaki C, Shimoi T, Sumiyoshi Okuma H, Kawachi A, Sudo K, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Arakawa A, Ogawa C, Yoshida A, Fujiwara Y, Tamura K. Inagaki C, et al. Among authors: kodaira m. Med Oncol. 2019 May 18;36(7):58. doi: 10.1007/s12032-019-1279-8. Med Oncol. 2019. PMID: 31104192
Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Tanaka R, Yonemori K, Hirakawa A, Kinoshita F, Takahashi N, Hashimoto J, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Fujimoto M, Fujiwara Y, Tamura K. Tanaka R, et al. Among authors: kodaira m. Oncologist. 2016 Apr;21(4):508-13. doi: 10.1634/theoncologist.2015-0377. Epub 2016 Mar 14. Oncologist. 2016. PMID: 26975863 Free PMC article.
265 results